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Summary
Background Bictegravir co-formulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination is 
recommended for treatment of HIV-1-infection and might be better tolerated than other integrase inhibitor-based 
single-tablet regimens, but long-term outcomes data are not available. We assessed the efficacy, safety and tolerability 
of bictegravir, emtricitabine, and tenofovir alafenamide compared with co-formulated dolutegravir, abacavir, and 
lamivudine at week 96.
Methods This ongoing, randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial was 
done at 122 outpatient centres in nine countries. We enrolled adults (aged ≥18 years) living with HIV who were 
treatment naive and HLA-B*5701 negative, did not have hepatitis B virus infection, and had an estimated glomerular 
filtration rate of at least 50 mL/min. We randomly assigned participants (1:1) to receive co-formulated bictegravir 
50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg (the bictegravir group) or co-formulated dolutegravir 
50 mg, abacavir 600 mg, and lamivudine 300 mg (the dolutegravir group), each with matching placebo, once daily for 
144 weeks. Treatment allocation was masked to all participants and investigators. All participants who received at least 
one dose of study drug were included in primary efficacy and safety analyses. We previously reported the primary 
endpoint. Here, we report the week 96 secondary outcome of proportion of participants with plasma HIV-1 RNA less 
than 50 copies per mL at week 96 by US Food and Drug Administration snapshot algorithm, with a prespecified 
non-inferiority margin of –12%. This study was registered with ClinicalTrials.gov, number NCT02607930.
Findings Between Nov 13, 2015, and July 14, 2016, we screened 739 participants, of whom 108 were excluded and 
631 enrolled and randomly assigned to bictegravir, emtricitabine, and tenofovir alafenamide (n=316) or dolutegravir, 
abacavir, and lamivudine (n=315). Two participants in the bictegravir group did not receive at least one dose of their 
assigned drug and were excluded from analyses. At week 96, bictegravir, emtricitabine, and tenofovir alafenamide 
was non-inferior to dolutegravir, abacavir, and lamivudine, with 276 (88%) of 314 participants in the bictegravir group 
versus 283 (90%) of 315 participants in the dolutegravir group achieving HIV-1 RNA less than 50 copies per mL 
(difference −1·9%; 95% CI –6·9 to 3·1). The most common adverse events were nausea (36 [11%] of 314 for the 
bictegravir group vs 76 [24%] of 315 for the dolutegravir group), diarrhoea (48 [15%] vs 50 [16%]), and headache 
(41 [13%] vs 51 [16%]). 36 (11%) participants in the bictegravir group versus 39 (12%) participants in the dolutegravir 
group had a serious adverse event. Two individuals died in the bictegravir group (recreational drug overdose and 
suicide, neither of which was treatment related) and none died in the dolutegravir group. No participants discontinued 
because of adverse events in the bictegravir group compared with five (2%) of 315 in the dolutegravir group. Study 
drug-related adverse events were reported for 89 (28%) participants in the bictegravir group and 127 (40%) in the 
dolutegravir group.
Interpretation These week 96 data support bictegravir, emtricitabine, and tenofovir alafenamide as a safe, well 
tolerated, and durable treatment for people living with HIV-1 with no emergent resistance.
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Introduction
The evolution of HIV therapeutics has been marked 
by a shift from multiple pill regimens given two 
to three times per day to once-daily, single-tablet 
formulations with improved potency and tolerability. 
Two single-tablet regimens are recommended as initial 
therapy of HIV-1 infection by major treatment guideline 
panels: co-formulated bictegravir, emtricitabine, and 
tenofovir alafenamide and co-formulated dolutegravir, 
abacavir, and lamivudine.1–3
These regimens containing integrase strand transfer 
inhibitors (INSTIs) are free from pharmacological boosters, 
and therefore have few drug interactions and can be taken 
with or without food. Both are also recommended for 
individuals regardless of pre treatment HIV-1 RNA level or 
CD4 cell count. Dolutegravir, abacavir, and lamivudine 
cannot be used in individuals who have the HLA-B*5701 
allele associated with hyper sensitivity to abacavir, are 
co-infected with hepatitis B virus, or have an estimated 
glomerular filtration rate (eGFR) less than 50 mL/min.2,4 
By contrast, bictegravir, emtricitabine, and tenofovir 
alafenamide can be used in such individuals and is 
approved for those with an eGFR greater than 30 mL/min.2,5
Although both regimens have been shown in clinical 
trials to be potent and well tolerated, they had not 
previously been directly compared until this randomised 
controlled trial, comparing these two regimens in adults 
living with HIV and without previous antiretroviral 
therapy. We previously reported the primary endpoint at 
48 weeks after the start of treatment, showing that 
bictegravir, emtricitabine, and tenofovir alafenamide was 
non-inferior to dolutegravir, abacavir, and lamivudine; 
virological failure was rare and treatment resistance was 
not detected in any participants.6 However, bictegravir, 
emtricitabine, and tenofovir alafenamide had better 
gastrointestinal tolerability in adverse event reporting 
and patient-reported outcome questionnaires.6,7
Here, we report on the 96-week outcomes of this trial 
to provide longer-term data on the relative efficacy and 
safety, including tolerability and renal, bone, and lipid 
Research in context
Evidence before this study
We searched PubMed on Jan 30, 2019, for randomised clinical 
trials of dolutegravir and bictegravir in people living with HIV-1, 
with title or abstract search terms of “dolutegravir” and 
“bictegravir” and “randomised” or “randomized”. We used 
internet search engines to identify governmental, 
non-governmental, and professional medical society practice 
guidelines relevant to bictegravir and dolutegravir. Searches 
were limited to English language publications between 
Jan 1, 1997, and Jan 30, 2019. Our search yielded reports of 
week-48 outcomes from six phase 2 and phase 3 studies of 
bictegravir, emtricitabine, and tenofovir alafenamide in 
treatment-naive and treatment-experienced participants. 
Included in these articles were the week-48 outcomes from this 
clinical trial (GS-US-380-1489), which showed non-inferior 
efficacy and less nausea with bictegravir, emtricitabine, 
and tenofovir alafenamide than with dolutegravir, abacavir, 
and lamivudine in treatment-naive participants at that 
timepoint. Three other phase 3 studies showed non-inferior 
efficacy of bictegravir, emtricitabine, and tenofovir alafenamide 
and confirmed safety at week 48; one in treatment-naive 
participants compared with dolutegravir, emtricitabine, 
and tenofovir alafenamide and two in virologically suppressed 
participants switching to bictegravir, emtricitabine, 
and tenofovir alafenamide compared with continuing either 
dolutegravir, abacavir, and lamivudine or a protease 
inhibitor-based regimen. Through 48 weeks, co-formulated 
bictegravir, emtricitabine, and tenofovir alafenamide had a 
similar renal, bone, and lipid safety profile relative to most 
comparators, with improved fasting lipid profile for those 
switched away from a boosted protease inhibitor, abacavir, 
and lamivudine. Based on week 48 data from the phase 3 trials, 
co-formulated bictegravir, emtricitabine, and tenofovir 
alafenamide became a guidelines-recommended regimen for 
initial treatment of adults with HIV, although longer-term data 
are needed to inform clinical care.
Added value of this study
This study is a randomised, double-blind phase 3 trial and 
among the first to provide evidence of the longer-term safety 
and efficacy of bictegravir, emtricitabine, and tenofovir 
alafenamide through 96 weeks. Compared with another 
guidelines-recommended treatment regimen (dolutegravir, 
abacavir, and lamivudine), co-formulated bictegravir, 
emtricitabine, and tenofovir alafenamide showed non-inferior 
efficacy. No participants on either regimen had virological failure 
with emergent resistance, further demonstrating the high 
barrier to resistance of the study regimens. Similar to week 48, 
nausea and other drug-related adverse effects were fewer in 
those treated with co-formulated bictegravir, emtricitabine, 
and tenofovir alafenamide than those treated with dolutegravir. 
This study provides longer-term data to support the durable 
efficacy and continued tolerability of bictegravir, emtricitabine, 
and tenofovir alafenamide, with no treatment-emergent 
resistance. Data from this trial also offers a continued look at the 
different safety profiles of these two single-tablet regimens.
Implications of all the available evidence
Data from this study complement those from another 
96-week report of co-formulated bictegravir, emtricitabine, 
and tenofovir alafenamide versus dolutegravir with 
emtricitabine and tenofovir alafenamide in treatment-naive 
individuals. Co-formulated bictegravir, emtricitabine, 
and tenofovir alafenamide can be administered once daily, 
does not require HLA B*5701 testing, and provides 
guideline-recommended therapy for people with HIV and with 
HIV and hepatitis B virus co-infection. The efficacy of 
switching to co-formulated bictegravir, emtricitabine, 
and tenofovir alafenamide in people with virological 
suppression on other antiretroviral regimens has been shown 
in different populations of patients. Together, these studies 
offer longer-term efficacy and safety data to guide treatment 
decisions for people living with HIV-1.
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profiles, of these two once-daily, single-tablet, INSTI-
containing regimens in individuals without previous 
HIV-1 therapy.
Methods
Study design and participants
This randomised, double-blind, multicentre, active-
controlled, phase 3, non-inferiority trial was done at 
122 outpatient centres in nine countries: Belgium, 
Canada, Dominican Republic, France, Germany, Italy, 
Spain, the UK, and the USA. Detailed methods have 
been previously published.6 Briefly, study investigators 
enrolled adults (aged ≥18 years) with HIV-1 infection who 
were treatment naive, did not have HLA-B*5701 mutation 
or hepatitis B virus infection, and had eGFR of at least 
50 mL/min (calculated by the Cockcroft–Gault equation). 
This study was done in accordance with the Declaration 
of Helsinki and was approved by central or site-specific 
review boards or ethics committees. All participants gave 
written informed consent.
Randomisation and masking
We randomly assigned participants (1:1) to either the 
bictegravir group (bictegravir, emtricitabine, and tenofovir 
alafenamide) or dolutegravir group (dolutegravir, abacavir, 
and lamivudine). Participants also received placebo 
tablets matching the alternative treatment. Randomisation 
was stratified b y H IV-1 R NA ( ≤100 0 00 c opies p er m L, 
100 001–400 000 copies per mL, or >400 000 copies 
per mL), CD4 count (<50 cells per μL, 50–199 cells per μL, 
or ≥200 cells per μL), and region (in the USA or outside 
the USA) at screening.
Procedures
Participants were given once-daily, oral fixed-dose 
combination of either bictegravir 50 mg, emtricitabine 
200 mg, and tenofovir alafenamide 25 mg or 
dolutegravir 50 mg, abacavir 600 mg, and lamivudine 
300 mg. Both regimens were given without regard to 
food. We did study visits at weeks 4, 8, and 12 after 
baseline, and every 12 weeks thereafter, with masked 
treatment visits planned until week 144 as previously 
reported.6 Laboratory tests included haematological 
analysis, serum chemistry tests, fasting lipids, CD4 
counts, renal function (eGFR, urine albumin-to-
creatinine ratio, retinol binding protein-to-creatinine 
ratio, β2-microglobulin-to-creatinine ratio; Covance 
Laboratories, Indianapolis, IN, USA), and HIV-1 RNA 
plasma measurements (Roche TaqMan 2.0; Roche 
Diagnostics, Rotkreuz, Switzerland). Protocol-defined 
resistance testing (Monogram Biosciences Inc, San 
Francisco, CA, USA) was done for any participant who 
had HIV-1 RNA of at least 50 copies per mL with a 
confirmed HIV-1 RNA of at least 200 copies per mL at 
the consecutive visit, or who had HIV-1 RNA of at least 
200 copies per mL at week 48, week 96, or the last visit 
on study drug after week 8, and who did not 
subsequently have HIV-1 RNA less than 50 copies per 
mL while on study drug.
We did dual-energy x-ray absorptiometry scans for hip 
and lumbar spine bone mineral density before drug 
administration at baseline and then at weeks 24, 48, 
and 96. One centre masked to treatment group 
assignment read all scans (BioClinica, Newtown, PA, 
USA). Safety was assessed by physical examinations, 
laboratory tests, 12-lead electrocardiogram, concomitant 
drugs, and recording of adverse events, which were 
coded with the Medical Dictionary for Regulatory 
Activities (MedDRA, version 21.0). Relatedness of adverse 
events to blinded study drugs was assessed by the 
investigator in a binary manner (yes or no).
Outcomes
We previously reported the primary outcome:6 the 
proportion of participants who had plasma HIV-1 RNA 
less than 50 copies per mL at week 48, as defined by the 
US Food and Drug Administration (FDA) snapshot 
algorithm.6,8 Secondary analyses of efficacy were planned 
for week 96 and week 144 using the same methods. Here 
we report the 96 week results.
We also assessed virological efficacy at week 96 in 
prespecified subgroups of age, sex, race, baseline HIV-1 
RNA, baseline CD4 cell count, geographic region, and 
study medication adherence. Other secondary efficacy 
analyses included the proportion of participants with 
plasma HIV-1 RNA less than 50 copies per mL at week 96 
when imputing missing as failure and missing as excluded 
data; the proportion of participants with plasma HIV-1 
RNA <20 copies per mL at week 96 by snapshot algorithm; 
change from baseline in CD4 cell count; and changes from 
baseline in hip and lumbar spine bone mineral density.
Adverse event incidence and changes in fasting lipids at 
week 96 were assessed by treatment group. Renal safety 
assessments included the change from baseline in serum 
creatinine and eGFR at week 96, treatment-emergent 
proteinuria through week 96, and percentage changes 
from baseline in urine retinol binding protein to creatinine 
ratio, urine β2-microglobulin-to-creatinine ratio and urine 
albumin-to-creatinine ratio at week 96.
Statistical analysis
Sample size justification was previously reported based on 
the primary outcome.6 Statistical analyses at week 96 
followed the same methods previously reported for 
week 48. We assessed plasma HIV-1 RNA less than 
50 copies per mL at week 96 (between days 631 and 714, 
inclusive) in the full analysis set (all participants who 
received at least one dose of their assigned study drug) 
either when participants had completed their week 96 
study visit or had prematurely discontinued the study drug. 
We did a per-protocol analysis excluding participants who 
had measurements missing for HIV-1 RNA at week 96 
(unless this was due to discontinuation because of no 
efficacy), low adherence (ie, adherence at or below the 
2·5th percentile among those in the study), or were taking 
medications prohibited by the protocol at study entry.
Change from baseline in CD4 cell count at week 96 
was summarised by treatment group with descriptive 
statistics based on the full analysis set using observed 
on-treatment data.
We summarised baseline characteristics with 
descriptive statistics for the safety analysis set, which 
included all randomly assigned participants who received 
at least one dose of study drug. For categorical data, we 
calculated p values using the Cochran-Mantel-Haenszel 
test (general association statistic was used for nominal 
data, the row mean scores differ statistic was used for 
ordinal data) for treatment comparison. For continuous 
data, we used the two-sided Wilcoxon rank-sum test. We 
used Fisher’s exact test for any adverse events occurring 
with a more than 5% difference in incidence between 
treatment groups. For bone mineral density data, the 
p values, the differences in percentage changes from 
baseline between treatment groups, and their 95% CIs 










Age, years 31 (25–41) 32 (26–40)
Sex
Women 29 (9%) 33 (10%)
Men 285 (91%) 282 (90%)
Race
White 180 (57%) 179 (57%)
Black 114 (36%) 112 (36%)
Asian 6 (2%) 10 (3%)
Ethnicity*
Hispanic or Latino 72 (23%) 65 (21%)
Not Hispanic or Latino 240 (77%) 249 (79%)
HIV disease status
Asymptomatic 286 (91%) 286 (91%)
Symptomatic 16 (5%) 14 (4%)
AIDS 12 (4%) 15 (5%)
HIV risk factor†
Heterosexual sex 61 (19%) 62 (20%)
Homosexual sex 251 (80%) 250 (79%)
Intravenous drug use 5 (2%) 4 (1%)
HIV-1 RNA, log10 copies per mL 4·42 (4·03–4·87) 4·51 (4·04–4·87)
HIV-1 RNA concentration category, copies per mL
≤100 000 261 (83%) 265 (84%)
>100 000 53 (17%) 50 (16%)
Median CD4 count, 
cells per μL
443 (299–590) 450 (324–608)
CD4 cell count category, cells per μL
<200 36 (11%) 32 (10%)
200–499 156 (50%) 149 (47%)
≥500 122 (39%) 134 (43%)
Creatinine clearance by 
Cockcroft–Gault formula, 
mL/min
126 (108–146) 123 (107–144)
Body-mass index, kg/m² 25·1 (22·4–28·7) 24·9 (22·5–29·1)
Primary resistance-associated mutations
INSTI‡ 4 (1%) 4 (1%)
NRTI§ 6 (2%) 5 (2%)
NNRTI¶ 36 (11%) 51 (16%)
Protease inhibitor|| 12 (4%) 11 (3%)
Data are median (IQR) or n (%). INSTI=integrase strand transfer inhibitor. 
NRTI=nucleoside reverse transcriptase inhibitor. NNRTI=non-nucleoside reverse 
transcriptase inhibitor. *Collection of race and ethnicity data was not permitted 
for two participants in the bictegravir group and one in the dolutegravir group per 
local regulations. †A participant may fit more than one HIV risk factor category. 
‡Thr66Ala/Ile/Lys, Glu92Gly/Gln, Thr97Ala, Phe121Tyr, Tyr143Cys/His/Arg, 
Ser147Gly, Gln148His/Lys/Arg, Asn155His/Ser, Arg263Lys. §Met41Leu, 
Lys65Glu/Asn/Arg, Asp67Asn, Thr69 insertions, Lys70Glu/Arg, Leu74Ile/Val, 
Tyr115Phe, Gln151Met, Met184Val/Ile, Leu210Trp, Thr215Tyr/Phe, 
Lys219Glu/Asn/Gln/Arg. ¶Leu100Ile, Lys101Glu/Pro, Lys103Asn/Ser, 
Val106Ala/Met, Val108Ile, Glu138Ala/Gly/Lys/Gln/Arg, Val179Leu, 
Tyr181Cys/Ile/Val, Tyr188Cys/Leu/His, Gly190Ala/Glu/Gln/Ser, His221Tyr, 
Pro225His, Phe227Cys, Met230Ile/Leu. ||Asp30Asn, Val32Ile, Met46Ile/Leu, 
Ile47Ala/Val, Gly48Val, Ile50Val/Leu, Ile54Leu/Met, Gln58Glu, Thr74Pro, 
Leu76Val, Val82Ala/Phe/Leu/Thr/Ser, Asn83Asp, Ile84Val, Asn88Ser, Leu90Met.  
Table 1: Baseline demographic and clinical characteristics
Figure 1: Trial profile through week 96
739 individuals assessed for eligibility
631 participants enrolled
108 excluded
89 did not meet eligibility criteria
8 lost to follow-up
6 withdrew consent
2 investigator decision
1 screened outside protocol-defined visit window
1 adverse event
1 incarcerated





3 non-compliance with drug
2 protocol violation
9 participant decision
12 lost to follow-up
315 randomly assigned to the dolutegravir, 
abacavir, and lamivudine group







2 non-compliance with drug
1 protocol violation
9 participant decision
17 lost to follow-up
316 randomly assigned to the bictegravir, 
emtricitabine, and tenofovir alafenamide 
group
2 did not receive drug 
including treatment group as a fixed-effect in the model. 
No adjustments were made for multiple comparison; all 
p values for secondary outcomes were exploratory.
We used SAS software version 9.4 (SAS Institute Inc, 
Cary, NC, USA) for all analyses. We assessed non-inferiority 
with a conventional 95% CI approach for the difference 
in proportion of patients with a virological response 
(bictegravir group minus dolutegravir group) with a 
prespecified n on-inferiority m argin o f – 12%, b ased o n 
published US FDA regulatory guidance.9
This study was done according to protocol without 
substantial deviations and is registered with ClinicalTrials. 
gov, number NCT02607930.
Role of the funding source
The funder of the study had the lead role in study design, 
data collection, data analysis, data interpretation and, along 
with DAW, writing of the manuscript. The corresponding 
author had full access to all the data in the study and 
had final r esponsibility f or t he d ecision t o s ubmit f or 
publication.
Results
Between Nov 13, 2015, and July 14, 2016, 739 participants 
were screened for this study, of whom 108 were excluded 
and 631 were enrolled. 316 participants were assigned to 
the bictegravir group and 315 to the dolutegravir group 
(figure 1 ). O f t hese, 3 14 r eceived a t l east o ne d ose 
of bictegravir, emtricitabine, and tenofovir alafenamide 
and 315 of dolutegravir, abacavir, and lamivudine. 
Demographics and baseline characteristics were balanced 
between the two treatment groups (table 1).
At 96 weeks, 276 (88%) of 314 participants in the 
bictegravir group had plasma HIV-1 RNA less than 
50 copies per mL compared with 283 (90%) of 315 in the 
dolutegravir group (difference −1·9%, 95% CI −6·9 to 3·1; 
table 2, figure 2); therefore, the bictegravir regimen was 
non-inferior to the dolutegravir regimen in the US FDA 
snapshot analysis. Two (1%) participants in the bictegravir 
group and seven (2%) in the dolutegravir group had 
HIV-1 RNA of 50 copies per mL or more at week 96 or 
when last tested. Differences existed between treatment 
groups in the subgroups with cumulative adherence less 
than 95% and those who were older than 50 years 
(appendix p 7). In both cases, the difference was driven by 
participants who did not have available data in the analysis 
window and whose last on-treatment assessment of 
HIV-1 RNA was less than 50 copies per mL (appendix 
pp 5–6), rather than any evidence of virological failure. 
No significant d ifferences we re de tected be tween th e 
two treatments in the other subgroups and no interactions 
between treatment and subgroup for other prespecified 
subgroups, including baseline viral load and CD4 strata 
(appendix p 7).
The proportion of participants with HIV-1 RNA less 
than 20 copies per mL at week 96 by FDA snapshot 
algorithm was 262 (83%) of 314 participants in the 
bictegravir group and 267 (85%) of 315 in the dolutegravir 
group (percentage difference –1·2%, 95% CI –6·9 to 4·6).
In the per-protocol analysis, the proportion of 
participants with HIV-1 RNA less than 50 copies per mL 
was high in both treatment groups: 275 (>99%) of 276 
for bictegravir, emtricitabine, and tenofovir alafenamide 
and 278 (99%) of 281 for dolutegravir, abacavir, and 
lamivudine (difference 0·7%, 95% CI –1·3 to 2·7). 
Results from the missing as failure and missing as 
excluded analyses were consistent with the main 
analysis (table 2). CD4 cell count increased in both 
treatment groups, with mean changes from baseline at 
week 96 of 287 (SD 207) cells per μL in the bictegravir 
group and 288 (247) cells per μL in the dolutegravir 
group.
Five participants with protocol-defined criteria for 
resistance testing were included in the week 96 resistance 
analysis population; all were in the dolutegravir, abacavir, 
and lamivudine group. One discontinued study drug 
before week 48, two had resistance testing before week 48 
and again met criteria and discontinued study drug 
between weeks 48 and 96, and two met criteria and 












HIV-1 RNA <50 copies per mL 276 (88%) 283 (90%) –1·9% (–6·9 to 3·1)
HIV-1 RNA ≥50 copies per mL 2 (1%) 7 (2%) ··
HIV1 RNA ≥50 copies per mL at week 96 
window
1 (<1%) 3 (1%) ··
Discontinued because of no efficacy 0 0 ··
Discontinued because of other reasons† and 
last available HIV-1 RNA ≥50 copies per mL
1 (<1%) 4 (1%) ··
No virological data at week 96 window 36 (11%) 25 (8%) ··
Discontinued because of adverse event or 
death‡
1 (<1%) 5 (2%) ··
Discontinued because of other reasons† and 
last available HIV-1 RNA <50 copies per mL
32 (10%) 17 (5%) ··
Missing data but on study drug 3 (1%) 3 (1%) ··
HIV-1 RNA <50 copies per mL by missing as 
failure§
276/314 (88%) 286/315 (91%) –2·9% (–7·8 to 2·1)
HIV-1 RNA <50 copies per mL by missing as 
excluded§
276/279 (99%) 286/288 (99%) –0·4% (–2·5 to 1·7)
HIV-1 RNA <20 copies per mL 262/314 (83%) 267/315 (85%) –1·2% (–6·9 to 4·6)
HIV-1 RNA <50 copies per mL by per-protocol 
analysis
275/276 (>99%) 278/281 (99%) 0·7% (–1·3 to 2·7)
Data are n (%) and % (95% CI). The week 96 window is between days 631 and 714 (inclusive). *The difference in 
percentages of participants with HIV-1 RNA <50 copies per mL between treatment groups and its 95% CI were 
calculated based on the Mantel-Haenszel proportions adjusted by baseline HIV-1 RNA stratum and region stratum. 
†Other reasons include investigator’s decision, participant decision, lost to follow-up, non-compliance with study 
drug, protocol violation, pregnancy, and study termination by funder. ‡One death in the bictegravir, emtricitabine, 
and tenofovir alafenamide occurred after the participant achieved the week 96 outcome. §Difference in percentages 
and 95% CIs are based on a dichotomised response: HIV-1 RNA <50 copies per mL versus HIV-1 RNA ≥50 copies per mL; 
patients with missing HIV-1 RNA at week 96 were considered ≥50 copies per mL for missing as failure approach and 
were excluded for missing as excluded approach.
Table 2: Virological outcomes at week 96
the bictegravir group who met inclusion criteria for 
resistance analysis at week 48 achieved HIV-1 RNA of less 
than 50 copies per mL on study drug and, therefore, is not 
included in the resistance analysis population at week 96. 
No emergent resistance developed to any component of 
either treatment regimen. Baseline primary nucleoside 
reverse transcriptase inhibitor (NRTI) resistance-associated 
mutations were present in 11 (2%) participants and 
consisted of Tyr115Phe or thymidine analogue mutations.10 
Baseline integrase geno typing data was assessed retro-
spectively by deep sequencing and analysed at mutation 
frequencies of at least 15%. Pretreatment INSTI resistance-
associated mutations were present in eight (1%) participants; 
one had Gln148His and Gly140Ser substitutions at greater 
than 99% frequency and seven had Thr97Ala. The presence 
of NRTI or INSTI resistance-associated mutations did not 
impact treatment outcomes. Notably, the participant with 
Gln148His and Gly140Ser (confirmed by population Sanger 
sequencing, with phenotypic resistance to raltegravir and 
elvitegravir, partial sensitivity to dolutegravir, and full 
sensitivity to bictegravir) was in the bictegravir group and 
had HIV-1 RNA less than 50 copies per mL at week 96.
Both treatments were generally well tolerated, with most 
adverse events reported as mild or moderate in severity. 
The most common adverse events were nausea, which was 
more common in the dolutegravir group than the 
bictegravir group (p=0·0001), diarrhoea, and headache 
(table 3). Prevalence and incidence of nausea declined over 
the 96-week study period (appendix p 10). No participants 
in the bictegravir group had adverse events that led to 
study drug discontinuation, whereas five (2%) participants 
in the dolutegravir group did. No neuropsychiatric adverse 
events met the more than 5% difference in incidence 
threshold for statistical testing. However, the frequency of 
dizziness and sleep disorder (MedDRA preferred terms) 
were two times higher in the dolutegravir group than in 
the bictegravir group (18 [6%] of 315 vs nine [3%] of 314 for 
dizziness and 13 [4%] vs three [1%] for sleep disorder). 
36 (11%) participants in the bictegravir group versus 
39 (12%) participants in the dolutegravir group had a 
serious adverse event. Five participants had adverse events 
that led to study drug discontinuation in the dolutegravir 
group: one nausea and generalised rash (day 4); 
one thrombocytopenia (day 50); one chronic pancreatitis 
and steatorrhoea (day 134); one depression (day 248); and 
one renal failure (day 621). All except the renal failure were 
considered by the investigator to be related to study drugs; 
all were grade 3 except one nausea and one depression, 
which were grade 2 (table 3). Participants in the bictegravir 
group had a lower incidence of drug-related adverse events 
than did those in the dolutegravir group (89 [28%] of 314 vs 
127 [40%] of 315, p=0·002); these events were primarily 
mild or moderate in severity and most occurred before 
HIV-1 RNA
<50 copies per mL
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Figure 2: Virological outcomes at week 96
Bictegravir group=bictegravir, emtricitabine, and tenofovir alafenamide group. 










All adverse events 292 (93%) 302 (96%)
Adverse event in at least 10% of participants
Nausea 36 (11%) 76 (24%)
Diarrhoea 48 (15%) 50 (16%)
Headache 41 (13%) 51 (16%)
Upper respiratory tract infection 33 (11%) 51 (16%)
Nasopharyngitis 36 (11%) 39 (12%)
Syphilis 27 (9%) 39 (12%)
Fatigue 27 (9%) 35 (11%)
Back pain 25 (8%) 30 (10%)
Insomnia 22 (7%) 31 (10%)
Grade 3 or 4 adverse events 42 (13%) 37 (12%)
Serious adverse events 36 (11%) 39 (12%)
Study drug-related adverse events 89 (28%) 127 (40%)
Study drug-related adverse events in at least 5% of participants
Nausea 18 (6%) 55 (17%)
Diarrhoea 19 (6%) 13 (4%)
Headache 16 (5%) 16 (5%)
Study drug-related serious adverse 
events
3 (1%)* 1 (<1%)
Any adverse events leading to study 
drug discontinuation
0 5 (2%)
Death 2 (1%) 0
Data are n (%). *One of these was reported as related at the time of analysis and 
was subsequently updated to unrelated when additional information was 
available to the investigator.
Table 3: Adverse events through week 96
week 48. The difference between groups was driven mainly 
by the significant difference in drug-related nausea which 
occurred in 18 (6%) of 314 in the bictegravir group versus 
55 (17%) of 315 in the dolutegravir group (p<0·0001). 
Study drug-related serious adverse events were originally 
reported for three participants in the bictegravir group 
(one sudden death, one generalised tonic-clonic seizure, 
and one spontaneous abortion) versus one patient in the 
dolutegravir group (gastro enteritis, steatorrhoea, and acute 
pancreatitis). One event in the bictegravir group (sudden 
death) was subsequently attributed to suicide and not 
related to study drug. Adverse events were similar to those 
reported at week 48, with no new safety findings between 
weeks 48 and 96 for either treatment group. No abnormal 
electrocardiogram findings w ere a ssociated w ith e ither 
treatment.
Between weeks 48 and 96, two deaths occurred, both 
in the bictegravir group. These events were recreational 
drug overdose (one) and suicide (one; in a participant 
with ongoing substance abuse); both events were 
considered unrelated to study treatment.
Three women had confirmed p regnancies w hile o n 
study, two in the bictegravir group and one in the 
dolutegravir group. One of the two participants in 
the bictegravir group was taken off s tudy t reatments 
when pregnancy was confirmed a nd s ubsequently 
delivered a healthy full-term infant. The other woman 
in the bictegravir group had a spontaneous abortion at 
an estimated 2 weeks’ gestation; the participant 
recovered from the event without complications. 
The pregnancy in the dolutegravir group was terminated 
with an elective abortion and study drugs were 
continued.
One or more grade 3 or 4 laboratory abnormalities were 
reported for 71 (23%) of 314 participants in the bictegravir 
group and 62 (20%) of 315 in the dolutegravir group; 
incidence and types of abnormalities were generally 
balanced between treatment groups (appendix p 8). Most 
abnormalities were transient and resolved on therapy. 
The overall laboratory safety profiles were similar to 
those observed at week 48. No proximal tubulopathy or 
Fanconi syndrome were reported in either group. No 
study participant in the bictegravir group discontinued 
because of a renal adverse event. One individual in the 
dolutegravir group with a medical history of poorly 
controlled diabetes and hypertension discontinued 
treatment because of an adverse event of renal failure on 
day 621. Small increases from baseline in median serum 
creatinine and decreases in eGFR occurred at week 96 
for both groups (table 4). At 96 weeks, percentage changes 
in quantitative proteinuria (total urinary albumin-to-
urine creatinine ratio) and tubular proteinuria (retinol 
binding protein and β2-microglobulin-to-urine creatinine 
ratios) were also similar between groups (table 4).
Changes from baseline in fasting high-density 
lipoprotein and triglycerides were similar between 
groups at week 96 (appendix p 9). Significant 
differences 
were measured in the median changes from baseline 
in fasting total cholesterol, low-density lipoprotein, 
and total cholesterol-to-high-density lipoprotein ratio at 
week 96 (appendix p 9). Initiation of lipid-modifying 
drugs during the study through week 96 was not 
different between the groups.
There were small changes from baseline in hip and 
lumbar spine bone mineral density that were similar 
between the two groups; mean percentage changes 
at week 96 in hip density were –1·13% (SD 2·77) in 
the bictegravir group versus –1·26% (2·85) in the 
dolutegravir group (p=0·59) and changes in lumbar 
spine density were –0·71% (3·87) versus –0·22% (3·52; 
p=0·14; figure 3). Weight increases after treatment 
initiation occurred in both groups. The median change 
was 3·6 kg (IQR 0·0–8·5) in the bictegravir group and 
2·4 kg (–0·4 to 5·8) in the dolutegravir group.
Discussion
Maximal and durable suppression of plasma HIV-1 
RNA as well as the enhancement of quality of life are 
among the major goals of treatment of HIV-1 infection.2 
Here, we report data showing non-inferiority of co-
formulated bictegravir, emtricitabine, and tenofovir 
alafenamide over co-formulated dolutegravir, abacavir, 
and lamivudine at 96 weeks after initiation in treatment-
naive people living with HIV-1 infection. Viral rebound 
was rare throughout the study. Overall, these virological 
outcomes data are consistent with those reported at 
week 48.6
Bictegravir, emtricitabine, 
and tenofovir alafenamide 
group (n=314)
Dolutegravir, abacavir, 
and lamivudine group 
(n=315)
p value
n Median (IQR) n Median (IQR)
Serum creatinine, mg/dL
Baseline 314 0·90 (0·80 to 1·00) 315 0·91 (0·81 to 0·99) 0·92
Change at week 96 277 0·08 (0·01 to 0·15) 286 0·09 (0·03 to 0·17) 0·067
Estimated glomerular filtration rate,* mL/min
Baseline 314 125·9 (107·7 to 146·3) 315 123·0 (107·0 to 144·3) 0·76
Change at week 96 277 –7·8 (–16·4 to 3·6) 286 –9·6 (–19·9 to –0·4) 0·01
Urine albumin-to-creatinine ratio, mg/g
Baseline 309 5·5 (3·7 to 9·2) 312 5·4 (3·7 to 9·1) 0·72
Percentage change at 
week 96
272 –0·3 (–33·5 to 59·6) 284 5·2 (–25·9 to 57·0) 0·25
Urine β2-microglobulin-to-creatinine ratio, μg/g
Baseline 307 108·1 (71·7 to 184·4) 311 109·8 (77·6 to 191·8) 0·92
Percentage change at 
week 96
271 –30·8 (–58·1 to 20·9) 283 –29·4 (–57·6 to 12·1) 0·96
Urine retinol binding protein-to-creatinine ratio, μg/g
Baseline 308 81·0 (58·3 to 122·4) 312 83·7 (59·8 to 120·4) 0·55
Percentage change at 
week 96
272 21·2 (–12·2 to 66·5) 284 22·1 (–12·8 to 78·7) 0·91
*As calculated by the Cockcroft–Gault formula. p values were calculated from the two-sided Wilcoxon rank-sum test to 
compare the two treatment groups.
Table 4: Changes in quantitative measures of proteinuria from baseline at week 96
As expected, given the inhibition of renal creatinine 
transporters by both bictegravir and dolutegravir, both 
groups had small median increases from baseline in 
serum creatinine and decreases in eGFR that occurred 
early and were sustained.11 Likewise, small but similar 
decreases in bone mineral density occurred in both study 
groups. Larger changes from baseline in total cholesterol 
and direct low-density lipoprotein cholesterol occurred in 
participants in the bictegravir group. Use of lipid-lowering 
therapy during the trial was low in both study groups, 
suggesting the clinical relevance of this 10 mg/dL 
difference between the two groups was minimal. The 
greater increase in low-density lipoprotein cholesterol in 
the bictegravir group was unexpected given previously 
reported week 48 data on the lipid profiles of both 
study regimens. Notably, in a study of treatment-naive 
individuals initiating bictegravir, emtricitabine, and 
tenofovir alafenamide versus dolutegravir, emtricitabine, 
and tenofovir alafenamide, significant differences in the 
median change in lipid concentrations at 96 weeks, 
including low-density lipoprotein cholesterol, were not 
observed.12
Several observational studies have described differential 
increases in weight after the initiation of or switch to 
different classes of antiretrovirals.13–15 Some, but not all, of 
these reports suggest that weight gain is greater among 
those treated with INSTIs.16–18 As expected for a treatment-
naive trial, median increases from baseline in weight were 
observed in both study groups. Longer-term trends in 
weight and the factors associated with changes from 
baseline will be examined in future planned analyses.
Overall, these results show that both regimens 
were efficacious and well tolerated. In distinguishing 
between the two, the higher frequency of investigator-
reported and patient-reported nausea should be 
considered. Additionally, the limitations of the use 
of dolutegravir, abacavir, and lamivudine, including 
among those with hepatitis B virus co-infection or 
with an eGFR less than 50 mL/min, as well as the 
requirement for HLA-B*5701 screening, might favour 
the use of bictegravir, emtricitabine, and tenofovir 
alafenamide in some individuals.
As described previously, there are limitations to this 
investigation that should be considered when inter-
preting these data. Foremost, the proportion of women 
enrolled in the trial was low. However, in a study that 
enrolled only women (n=470) with suppressed plasma 
HIV-1 RNA who were randomly assigned either to 
continue prestudy antiretroviral therapy or to switch 
to bictegravir, emtricitabine, and tenofovir alafenamide, 
more than 95% of the participants in each treatment 
group maintained viral suppression at week 48 with no 
discontinuations of study drug due to adverse events.19 
Neuropsychiatric adverse effects of INSTI-containing 
regimens have been previously reported; however, each 
individual adverse effect is described as relatively 
uncommon.20–22 Therefore, this trial probably had too few 
participants to detect differences between the regimens 
in any neuropsychiatric adverse event as reported 
by investigators. Furthermore, although 96-week data 
provide a valuable assessment of the durability of the 
efficacy and safety of these regimens, the need for HIV 
therapy remains lifelong. Longer-term data is needed to 
provide insights into the advantages and disadvantages 
of these therapeutic options. Participants in this study 
will continue to be followed up until week 144.
In summary, as was observed at week 48, bictegravir, 
emtricitabine, and tenofovir alafenamide after 96 weeks 
of therapy was non-inferior to dolutegravir, abacavir, and 
lamivudine, with no emergent drug resistance or 
tubulopathy detected, but with a better gastrointestinal 
tolerability profile. Bictegravir, emtricitabine, and tenofovir 
alafenamide can be used in those co-infected with hepatitis 
B virus and eGFRs as low as 30 mL/min and does not 
require HLA-B*5701 screening. Therefore, bictegravir, 
emtricitabine, and tenofovir alafenamide is a potent and 
well tolerated option for people with HIV-1 infection 
initiating treatment.
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Figure 3: Percentage change from baseline at weeks 24, 48, and 96 in lumbar spine and hip bone mineral 
density by dual-energy x-ray absorptiometry
Data points are means, error bars are 95% CIs. *p values are at week 96 by analysis of variance. 
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